Replies to post #176702 on Biotech Values

[jq1234]

ABBV/ENTA TURQUOISE-II cirrhotic patients 12-week: Overall SVR12=92% for 3-DAA plus RBV. For trt naive, SVR12=94%; for trt experienced, SVR12=90%.

http://www.nejm.org/doi/pdf/10.1056/NEJMoa1402869

[Generally speaking similar to ION-1, 2 cirrhotic patients taking consideration ION-2 included some Incivek/Victrelis treated.]

SAPPHIRE-I: trt naive.

http://www.nejm.org/doi/pdf/10.1056/NEJMoa1315722

SAPPHIRE-II: trt experienced.

http://www.nejm.org/doi/pdf/10.1056/NEJMoa1401561

[dewophile]

thx - on quick glance looks like cirrhotics could benefit from 24 weeks with either regimen - with the exception of GT1b patients who had outstanding results with 12 week of the ABBV regiment (i didnt see a breakdown in cirrhotics by genotype in ION studues - but numbers probably too small anyway to draw conclusion)

re ION-3 there were an unusually large number of pts ost to follow up in the 12 week arm compared to 8 week arms. the VIROLOGIC failure rate in the 12 week arm was 1% versus 4-5% in the 8 week arm, which is a small but still meaningful difference. If i were a patiient i wouldn't want 8 weeks of GILD's regimen (and i question now if they get approved for 8 weeks)